Cocrystal Pharma, Inc. 8-K

What Happened Cocrystal Pharma, Inc. (COCP) announced in an 8-K (Item 7.01, Regulation FD Disclosure) filed June 3, 2026 that James Sapirstein has been appointed Chief Executive Officer. The company furnished a press release announcing the appointment as Exhibit 99.1 to the filing.

Key Details

• Filing date: June 3, 2026 (Form 8-K, Item 7.01 Regulation FD Disclosure).
• Appointee: James Sapirstein named Chief Executive Officer.
• Press release: Announcement furnished as Exhibit 99.1 to the 8-K.
• The disclosure was furnished (press release) — the filing does not include additional financial statements or detailed executive compensation information.

Why It Matters A CEO appointment is a material leadership change that can affect company strategy, operations, and investor sentiment. This 8-K provides official disclosure of the leadership change but includes only a press release; investors should watch for follow-up SEC filings or company communications for details on Sapirstein’s start date, responsibilities, background, and any related compensation or governance changes.